J Menopausal Med.  2018 Apr;24(1):62-66. 10.6118/jmm.2018.24.1.62.

Gonadotropin-releasing Hormone Agonist Plus Aromatase Inhibitor in the Treatment of Uterine Leiomyoma in Near Menopause Patient: A Case Series Study

• Moradan S

• KMID: 2429222
• DOI: http://doi.org/10.6118/jmm.2018.24.1.62

Abstract

OBJECTIVES
There are many drugs for of symptomatic fibroids. Gonadotropin-releasing hormone (GnRH) agonists are the well known drugs. Also, aromatase inhibitors are effective. All published studies surveyed the effect of one of these two drugs. In this study as the first study decided to evaluate the effectiveness of the combination of GnRH agonists + aromatise inhibitor on the uterine fibroids.
METHODS
A cross-sectional prospective case series study was performed on 10 known cases of uterine fibroids late perimenopause, at least 3 myomas >5 cm, abnormal uterine bleeding and anemia due to fibroids, candidate for hysterectomy, no tendency to surgery. A single dose of Diphereline 11.25 mg, SR plus 2.5 mg of Letrozole daily for 4 weeks with add-back therapy + calcium carbonate were used. The second dose of Diphereline 11.25 mg, SR was used 3 months after the first injection. The patients were followed until 3 years.
RESULTS
The mean age of the study group was 49.90 ± 1.66. The mean fibroid size reduced from 15.05 ± 57.20 cm to 13.56 ± 39.39 cm (P = 0.012) and fibroid volume reduced from 72.78 ± 110.6 to 50.96 ± 64.2 (P = 0.116). There was no signification changes in the serum level of hormones at the end of six months. Eight cases were menopause at the end of the study and hypoestrogenism symptoms did not happened in none of the cases until the end of 24 months. Except in one case, there was no need to do surgery on others.
CONCLUSIONS
Combination of Diphereline + Letrozole probably could prevent surgery in cases that have multiple fibroids, perimenopause, anemic and candidate for surgery.

Keyword

Aromatase inhibitors; Gonadotropin-releasing hormone; Leiomyoma

MeSH Terms

Anemia
Aromatase Inhibitors
Aromatase*
Calcium Carbonate
Female
Gonadotropin-Releasing Hormone*
Humans
Hysterectomy
Leiomyoma*
Menopause*
Myoma
Perimenopause
Prospective Studies
Uterine Hemorrhage
Aromatase
Aromatase Inhibitors
Calcium Carbonate
Gonadotropin-Releasing Hormone

Reference

1. Parker WH. Uterine fibroids. In : Berek JS, Novak E, editors. Berek & Novak's gynecology. 15th ed. Philadelphiam PA: Lippincott Williams & Wilkins;2015. p. 438–469.

2. Song H, Lu D, Navaratnam K, Shi G. Aromatase inhibitors for uterine fibroids. Cochrane Database Syst Rev. 2013; Cd009505.

3. Oh SR, Cho YJ, Han M, Bae JW, Park JW, Rha SH. Uterine lipoleiomyoma in peri or postmenopausal women. J Menopausal Med. 2015; 21:165–170.

4. Jeong JH, Hong GP, Kim YR, Hong DG, Ha JE, Yeom JI, et al. Expulsion of fibroids to the endometrial cavity after magnetic resonance imaging-guided high intensity focused ultrasound surgery (MRgFUS) treatment of intramural uterine fibroids. J Menopausal Med. 2016; 22:139–145.

5. Koskas M, Chabbert-Buffet N, Douvier S, Huchon C, Paganelli E, Derrien J. Role of medical treatment for symptomatic leiomyoma management in premenopausal women. J Gynecol Obstet Biol Reprod (Paris). 2011; 40:858–874.

6. Han M, Kim JY, Park JE, Kim JM, Lee KS. Effects of letrozole on proliferation and apoptosis in cultured leiomyoma cells treated with prostaglandin E(2). Eur J Obstet Gynecol Reprod Biol. 2008; 138:83–88.

7. Gocmen A, Kara IH, Karaca M. The effects of add-back therapy with tibolone on myoma uteri. Clin Exp Obstet Gynecol. 2002; 29:222–224.

8. Gurates B, Parmaksiz C, Kilic G, Celik H, Kumru S, Simsek M. Treatment of symptomatic uterine leiomyoma with letrozole. Reprod Biomed Online. 2008; 17:569–574.

9. Duhan N, Madaan S, Sen J. Role of the aromatase inhibitor letrozole in the management of uterine leiomyomas in premenopausal women. Eur J Obstet Gynecol Reprod Biol. 2013; 171:329–332.

10. Parsanezhad ME, Azmoon M, Alborzi S, Rajaeefard A, Zarei A, Kazerooni T, et al. A randomized, controlled clinical trial comparing the effects of aromatase inhibitor (letrozole) and gonadotropin-releasing hormone agonist (triptorelin) on uterine leiomyoma volume and hormonal status. Fertil Steril. 2010; 93:192–198.

11. Koskas M, Derrien J. Medical treatment of symptomatic uterine leiomyomata in premenopausal woman. Presse Med. 2013; 42:1122–1126.

12. Ferrero S, Venturini PL, Remorgida V. Letrozole monotherapy in the treatment of uterine myomas. Fertil Steril. 2010; 93:e31. author reply e2.

13. Biri A, Korucuoglu U, Zumrutbas N, Tiras B, Guner H. Intravenous leiomyomatosis treated with aromatase inhibitor therapy. Int J Gynaecol Obstet. 2008; 101:299–300.

14. Yoon G, Kim TJ, Sung CO, Choi CH, Lee JW, Lee JH, et al. Benign metastasizing leiomyoma with multiple lymph node metastasis: a case report. Cancer Res Treat. 2011; 43:131–133.